SERNIVO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sernivo, and when can generic versions of Sernivo launch?
Sernivo is a drug marketed by Primus Pharms and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.
This drug has seven patent family members in five countries.
The generic ingredient in SERNIVO is betamethasone dipropionate. There are sixty-six drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sernivo
A generic version of SERNIVO was approved as betamethasone dipropionate by FOUGERA PHARMS on June 26th, 1984.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SERNIVO?
- What are the global sales for SERNIVO?
- What is Average Wholesale Price for SERNIVO?
Summary for SERNIVO
| International Patents: | 7 |
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 50 |
| Patent Applications: | 4,540 |
| Drug Prices: | Drug price information for SERNIVO |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SERNIVO |
| What excipients (inactive ingredients) are in SERNIVO? | SERNIVO excipients list |
| DailyMed Link: | SERNIVO at DailyMed |
Pharmacology for SERNIVO
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Paragraph IV (Patent) Challenges for SERNIVO
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| SERNIVO | Topical Spray | betamethasone dipropionate | 0.05% | 208079 | 1 | 2018-02-15 |
US Patents and Regulatory Information for SERNIVO
SERNIVO is protected by seven US patents.
Patents protecting SERNIVO
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PLAQUE PSORIASIS
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PLAQUE PSORIASIS
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PLAQUE PSORIASIS
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PLAQUE PSORIASIS
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PLAQUE PSORIASIS
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PLAQUE PSORIASIS
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PLAQUE PSORIASIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primus Pharms | SERNIVO | betamethasone dipropionate | SPRAY;TOPICAL | 208079-001 | Feb 5, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Primus Pharms | SERNIVO | betamethasone dipropionate | SPRAY;TOPICAL | 208079-001 | Feb 5, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Primus Pharms | SERNIVO | betamethasone dipropionate | SPRAY;TOPICAL | 208079-001 | Feb 5, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SERNIVO
See the table below for patents covering SERNIVO around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
